Evidence map›Paper›PMID 31904706›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2020

Higher Acuity Resource Utilization With Older Age and Poorer HIV Control in Adolescents and Young Adults in the HIV Research Network.

Anne M Neilan, Frances Lu, Kelly A Gebo, Rebeca Diaz-Reyes, Mingshu Huang, Robert A Parker, Brad Karalius, Kunjal Patel, Cindy Voss, Andrea L Ciaranello and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Economic Burden of HIV in a Commercially Insured Population in the United States.Journal of health economics and outcomes research · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Anne M NeilanDivision of General Academic Pediatrics, Department of Pediatrics, Massachusetts General Hospital, Boston, MA.
Frances LuThe Biostatistics Center, Massachusetts General Hospital, Boston, MA.
Kelly A GeboJohns Hopkins University School of Medicine, Baltimore, MD.
Rebeca Diaz-ReyesJohns Hopkins University School of Medicine, Baltimore, MD.
Mingshu HuangThe Biostatistics Center, Massachusetts General Hospital, Boston, MA.
Robert A ParkerHarvard Medical School, Boston, MA.
Brad KaraliusDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; and.
Kunjal PatelDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; and.
Cindy VossJohns Hopkins University School of Medicine, Baltimore, MD.
Andrea L CiaranelloDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Allison L AgwuJohns Hopkins University School of Medicine, Baltimore, MD.
Harvard University · USMassachusetts General Hospital · USJohns Hopkins Medicine · USJohns Hopkins University · US

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Sharon A Nachman · 2011 to 2026
$278.1M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SONIA JAIN · 1994 to 2026
$78.4M
University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Project-003U24HD089880 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUDGENS, MICHAEL G, LAVANGE, LISA · 2016 to 2021
$44.3M
Institutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)T32AI007433 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARK J SIEDNER · 1992 to 2026
$11.4M
Innovation across the spectrum of pediatric HIV care: Clinical impact and cost-effectiveness of long-acting antiretroviral therapy for breastfeeding people with HIV and their infants in ZimbabweR01HD079214 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI CIARANELLO, ANDREA LYNNE · 2014 to 2023
$8.0M
Diagnosing and preventing HIV infection in adolescents and young adults in the US: clinical impact and cost-effectivenessK08HD094638 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI NEILAN, ANNE · 2018 to 2023
$936k
NCATS NIH HHS UL1 TR000427NCATS NIH HHS UL1 TR002373NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI094189NIAID NIH HHS T32 AI007433NIAID NIH HHS UM1 AI068632NICHD NIH HHS K08 HD094638NICHD NIH HHS R01 HD079214NICHD NIH HHS U24 HD089880NIDA NIH HHS U01 DA036935
6 · The paper itself

Abstract

backgroundAdolescents and young adults (AYA) with HIV experience poorer health outcomes compared with adults. To improve care for AYA with HIV, information about patterns of costly health care resource utilization is needed.

methodsAmong 13-30 year olds in the US HIV Research Network, we stratified outpatient visits, emergency department (ED) visits, and inpatient days/person-year (PY) by HIV acquisition model [perinatal (PHIVY) and nonperinatal (NPHIVY)], age (13-17, 18-23, and 24-30 years), CD4 strata (<200, 200-499, and ≥500 cells/µL), and viral load (VL) suppression (<, ≥400 copies/mL [c/mL]) combined with antiretroviral (ARV) use.

resultsAmong 4540 AYA (PHIVY: 15%; NPHIVY: 85%), mean follow-up was 2.8 years. Among PHIVY, most person-time (PT) was spent between ages 13 and 23 years (13-17 years: 43%; 18-23 years: 45%), CD4 ≥500/µL (61%), and VL <400 c/mL (69%). Among NPHIVY, most PT was spent between ages 24 and 30 years (56%), with CD4 ≥500/µL (54%), and with VL <400 c/mL (67%). PT spent while prescribed ARVs and with VL ≥400 c/mL was 29% (PHIVY) and 24% (NPHIVY). For PHIVY and NPHIVY, outpatient visit rates were higher at younger ages (13-17 years and 18-23 years), lower CD4 (<200 and 200-499/µL), and among those prescribed ARVs. Rates of ED visits and inpatient days were higher during PT spent at older ages (18-23 years and 24-30 years), lower CD4 (<200 and 200-499/µL), and VL ≥400 c/mL. Utilization was higher among PHIVY than NPHIVY (outpatient: 12.1 vs. 6.0/PY; ED: 0.4 vs. 0.3/PY; inpatient: 1.5 vs. 0.8/PY).

conclusionsMore ED visits and inpatient days were observed during time spent at older ages, lower CD4 count, and VL ≥400 c/mL. Interventions to improve virologic suppression and immune response may improve outcomes, and thus decrease costly resource utilization, for AYA with HIV.

Indexed as

AgingAdolescentAdultAnti-Retroviral AgentsCD4 Lymphocyte CountDrug Administration ScheduleFemaleHIV-1HIV InfectionsHumansMaleMedication AdherenceViral LoadYoung AdultAnti-Retroviral Agents

Identifiers

PMID31904706
PMCPMC7055514
OpenAlexW2997968238

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.